Pharsight

1. Impoyz patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956231	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US10588914	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US10064875	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9855334	PRIMUS PHARMS	Topical compositions comprising a corticosteroid	Mar, 2035 (11 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: Treatment of moderate plaque psoriasis; Treatment of plaque psoriasis in patients 18 years of age or older; Psoriasis; Twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment ...

Dosage: CREAM;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.00025	06 Dec, 2019	1		11 Mar, 2035

Strength	Dosage	Availability
0.025%	CREAM;TOPICAL	Prescription

IMPOYZ family patents

2. Sernivo patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433630	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9877974	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9439911	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9775851	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9364485	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US9655907	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)
US10179137	PRIMUS PHARMS	Topical formulations comprising a steroid	Aug, 2030 (6 years from now)